Embedded Files
Recent Surge of Mucormycosis in COVID-19 Patients: Clinicians’ Perspective from Systems Genomics
Sudhir Mehta, Krishna Mohan Medicherla, Ayyagari Subramanyam, PB Kavi Kishor, Prashanth Suravajhala
MycoAsia 2022/04.
https://doi.org/10.59265/mycoasia.2022-04
Abstract
Mucormycosis has been largely associated with COVID-19 patients. With the growing number of cases, there is an immediate need to understand the treatment regimen for COVID-19 which could predispose to mucormycosis infection. The authors have highlighted the points from clinicians’ perspective.
Plain Language Summary
Mucormycosis, a serious fungal infection, has been increasingly reported in COVID-19 patients. With cases on the rise, there is an urgent need to figure out which specific COVID-19 treatments might be making patients more vulnerable to this secondary infection. This review examines the issue from a doctor’s perspective, highlighting the potential risk factors within the treatment process. Understanding this connection is a critical step toward preventing mucormycosis and ensuring safer outcomes for patients battling COVID-19.
Report abuse